SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (4277)5/19/2016 9:16:47 PM
From: jaybe  Read Replies (1) of 4474
 
Yes, abstract suggests IRC ORR, a secondary endpoint, will be presented at ASCO for comparison against the 44%.

It's also important to recall this datapoint from Ph1/2 trial at ASCO '15..."Of the 50 patients with prior crizotinib treatment who achieved a response, 38 (76%) achieved it by the first 8-week assessment and 46 (92%) achieved it by 16 weeks."

Since enrollment ended Sept 21st and data cut-off was Dec 7th its likely we will see more responses at ASCO. Just making a guess here but if 15-20 patients are in this window we could see additional 8-10 responses at ASCO, pushing ORR above ~60%.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News